July 21th, 2013
Oraculum Loquitur
https://theoptionsoracle.com/
July 21st, 2013
Introducing The Rowboat
Quite Possibly The Holy Grail of Investing.
Step 1: Sell the Put
( This is a Cash Covered Put, I have to have enough Cash to buy 100 shares per
contract if the option is exercised, this is also my maximum risk.)
GTXI @ $5.19
GTX Inc.
Sell To Open GTXI Aug 2013 $2 Put @ Market
currently .15c bid / .18c time
7.5% return in 25 days
How to do this trade and commentary Video:
http://www.youtube.com/watch?v=5PWW-X8ty_s&feature=youtu.be
GTx, Inc., a biopharmaceutical company, engages in the discovery,
development, and commercialization of small molecules for the treatment of
cancer, cancer supportive care, and other serious medical conditions. It is
involved in developing Enobosarm, an androgen receptor modulator, which is
in Phase III clinical trials for the prevention and treatment of muscle wasting
in patients with non-small cell lung cancer in the United States, Europe,
Russia, and South America. The company also develops Capesaris, an oral
nonsteroidal estrogen receptor alpha agonist that is in Phase II clinical trial
for secondary hormonal therapy in men with metastatic castration resistant
prostate cancer. In addition, its preclinical development stage products
include inhibitors of steroid biosynthetic enzymes, anticancer therapies,
estrogen receptor beta agonists, and other novel compounds for the potential
treatment of cancer, metabolic diseases, ophthalmic diseases, psoriasis, and
pain. GTx, Inc. was founded in 1997 and is headquartered in Memphis,
GTX Inc.

175 Toyota

Plaza 7th Floor

Memphis, TN 38103

Phone: 901-523-9700 Fax: 901-844-8075

Website: http://www.gtxinc.com

News:

HLF @ $55.80

Herbalife Ltd.

Sell To Open HLF Aug 2013 $50 Put @ Market

currently $2.32 bid / $2.40 time

4.64% return in 25 days

How to do this trade and commentary Video:

http://youtu.be/4BVZvC2K0Yg

Herbalife Ltd., a network marketing company, sells weight management, healthy meals and snacks, sports and fitness, energy and targeted nutritional products, and personal care products worldwide. It offers science-based products in four principal categories, including weight management; targeted nutrition; energy, sports, and fitness; and outer nutrition. The weight management product portfolio includes meal replacement, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. The targeted nutrition products comprise dietary and nutritional supplements containing quality herbs, vitamins, minerals, and other natural ingredients. The energy, sports, and fitness products consist of products designed to meet the nutritional needs of athletes, such as Herbalife24 product line, which enables athletes to customize their nutrition program based on personal training and competitive demands throughout the day. The outer nutrition products include skin cleansers, toners, moisturizers, facial masks, shampoos and conditioners, body -wash items, and a selection of fragrances for men and women, as well as anti-aging products. The company also sells literature and promotional materials, including International Business Packs , start-up kits, sales tools, and educational materials, as well as Internet based tools, such as BizWorks, a customizable retail Website for its distributors. Herbalife Ltd. offers its products through retail stores, sales representatives, sales officers, and independent service providers. The company was founded in 1980 and is based in Los Angeles, California.

Herbalife Ltd.

800 West Olympic Boulevard

Suite 406

Los Angeles, CA 90015

Phone: 310-410-9600
Website: http://www.herbalife.com
Remember, no more than 5 or 10% of your portfolio should ever go
into any one trade or position.

Step 2: IF it got Put to us, Now we “Lock-in” a profit.
Sell the Covered Call
(Do not buy a stock just to sell the covered Call)

Nothing got Put to us last month
News:

Remember, no more than 5 or 10% of your portfolio should ever go

into any one trade or position.

How did we do last Month?

BPI @ $15.55

Bridge point Education, Inc.
Put Options expired

06/24/2013 Sell To Open BPI Jul13 9 Put $0.15

1.66% return in 25 days

$10,000 would have generated $166.00

MDVN @ $56.37

Medivation, Inc.
Put Options expired

06/24/2013 Sell To Open MDVN Jul13 40 Put $1.41

3.52% return in 25 days

$10,000 would have generated $352.00

SCTY @ $41.67

SolarCity Corporation

Called away @ $40.00 move to closed positions

4.85% return in 32 days

History:

Cost basis $35.00 per share. Capital Gain: $5.00

Premiums collected: $2.00 per share Total: $7.00
20% Return in 2 months
$10,000 would have generated $2000.00

actual trades:

07/19/2013 Buy To Close SCTY JUL 2013 40 Call

07/19/2013 sell SCTY – Stock Assignment $40.00

06/24/2013 Sell To Open SCTY Jul13 40 Call $0.30
05/20/2013 Sell To Open SCTY Jun13 35 Put $1.70

Current/Older Positions/History

This includes a running total for each open position.
Do not enter these positions.

CLSN @ $1.42

Celsion Corporation
Put to us @ $2.00

Hold

No good options at this time.

Earnings date: August 9th

History:

Cost basis $2.00 per share. Premiums collected: $.50 per share 25% Return in 5 months

$10,000 would have generated $2500.00

actual trades:

02/19/2013 Sell To Open CLSN July 2013 $3 Call

(did not fill, because of Holiday) 0.00

02/15/2013 Buy CLSN – Option Assignment $2.00 01/22/2013 Sell To Open CLSN Feb13 2 Put $0.30 12/24/2012 Sell To Open CLSN Jan13 2 Put $0.20

Celsion Corporation, an oncology drug development company, engages in the development and commercialization of targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company develops ThermoDox, a liposomal encapsulation of doxorubicin, which is under Phase III clinical trial for primary liver cancer; under phase II clinical trial for colorectal liver metastasis; and under phase II clinical trial for treatment of recurrent chest wall breast cancer. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. for ThermoDox; a license agreement with Duke University to commercialize and use Duke’s thermo-liposome technology; and a joint research agreement with Royal Philips Electronics to evaluate the combination of Philips’ high intensity focused ultrasound with its ThermoDox to determine the potential of this combination to treat various cancers. The company was founded in 1982 and is based in Lawrenceville, New Jersey.

Celsion Corp.

997 Lenox Drive

Suite 100 Lawrenceville, NJ 08648

Phone: 609-896-9100 Fax: 609-896-2200

Website: http://www.celsion.com

News:

DMND @ $21.81

Put to us @ $32.00

Hold

No good options at this time

3.59% Return

History:

Cost basis $32.00 per share. Premiums collected: 1.15 per share 3.59% Return in 16 months

$10,000 would have generated $359.00

actual trades:

09/24/2012 Sell To Open DMND Dec12 30 Call $0.20 03/20/2012 Sell To Open DMND Jun12 33 Call $0.25 03/18/2012 Buy To Close EXPIRED DMND Mar12 32 CALL 02/21/2012 Sell To Open DMND Mar12 32 Call $0.20 02/17/2012 Buy DMND – Option Assignment $32.00 02/17/2012 Buy To Close DMND Feb12 32 Put 02/06/2012 Sell To Open DMND Feb12 32 Put $1.50

Diamond Foods, Inc. engages in processing, marketing, and distributing snack products. It provides snack products, including roasted, glazed and flavored nuts, trail mixes, dried fruit, seeds, microwave popcorn products, and potato and tortilla chips under the Emerald, Pop Secret, and Kettle brands. The company also offers culinary, in-shell, and ingredient nuts under the Diamond of California brand name. It markets its culinary nuts to individuals who prepare meals or baked goods at home; and ingredient nuts to food processors, restaurants, bakeries, and food service companies and their suppliers. The company sells its products directly to national grocery, mass merchandiser, clubs, convenience stores, and drug store chains in the United States, the United Kingdom, Germany, the Netherlands, Spain, Canada, South Korea, Turkey, China, and Japan. Diamond Foods, Inc. was founded in 1912 and is based in San Francisco, California.

Diamond Foods, Inc.

600 Montgomery Street 13th Floor

San Francisco, CA 94111-2702 Phone: 415-445-7444

Website: http://www.diamondfoods.com

News:

ELN @ $14.20

Called away, move to closed positions

History:

Cost basis $12.00 per share. Premiums collected: $1.80 per share Capital Gain $1.00

Total $2.80

23.33% Return in 10 months

$10,000 would have generated $2333.00

actual trades:

07/19/2013 ELN – Option Assignment $13.00 07/20/2013 Called away @ $13.00

04/22/2013 Sell To Open ELN Jul13 13 Call $0.05 01/22/2013 Sell To Open ELN Apr13 12 Call $0.10 10/22/2012 Sell To Open ELN Jan13 14 Call $0.10 08/20/2012 Sell To Open ELN Oct12 13 Call $0.35 07/23/2012 Sell To Open ELN Aug12 12 Put $1.20

Elan shareholders on the register on December 14, 2012, the record date, received 1 Prothena (PRTA) ordinary share for every 41 Elan ordinary shares or ADSs held.

PRTA @ $16.58

Elan Corporation, plc operates as a neuroscience-based biotechnology company in the United States, Ireland, and internationally. It engages in research, development, and commercial activities primarily in the areas of Alzheimer s disease, Parkinson s disease, and multiple sclerosis (MS). The company offers Tysabri, an alpha -4 integrin inhibitor primarily for the treatment of MS. It is also developing ELND005, a beta amyloid anti- aggregation agent to treat Alzheimer s disease, which completed Phase II clinical trial. In addition, the company focuses on the discovery and development of antibodies to neo-epitope related targets for the treatment of a range of indications, including amyloidosis, diabetes, cancer, and macular degeneration; and drugs for oncology related diseases comprising NEOD001 for the treatment of AL amyloidosis, as well as focuses on developing ELND005 for bipolar disorder. Further, the company, through collaboration agreement with Biogen Idec, Inc., develops and markets Tysabri for the treatment for Crohn s disease. Additionally, Elan Corporation, plc, through a 49.9% interest in Janssen AI, develops beta amyloid immunotherapies, including bapineuzumab, ACC-001, and other compounds to treat Alzheimer s disease.

The company also has collaboration agreements with Cambridge-Elan Centre, Dublin Neurological Institute, University College Dublin, and Proteostasis. Elan Corporation, plc was founded in 1969 and is headquartered in Dublin, Ireland.

Elan Corporation, plc

Treasury Building

Lower Grand Canal Street

Dublin, 2

Ireland

Phone: 353 1 709 4000

Fax: 353 1 709 4700

Website: http://www.elan.com
news

ONTY @ $1.65

HOLD no good options at this time

History:

Cost basis $5.00 per share. Premiums collected: 2.20 per share 44% Return in 19 months

$10,000 would have generated $4400.00

actual trades:

03/18/2013 Sell To Open ONTY Jun13 5 Call $0.05
11/19/2012 Sell To Open ONTY Jan13 6 Call $0.55
05/21/2012 Sell To Open ONTY Nov12 7 Call $0.05
03/20/2012 Sell To Open ONTY May12 6 Call $0.05
03/16/2012 Buy ONTY – Option Assignment $5.00
03/16/2012 Buy To Close ONTY Mar12 $5 Put
02/21/2012 Sell To Open ONTY Mar12 $5 Put $0.70
02/19/2012 Buy To Close EXPIRED ONTY FEB12 $5 PUT
01/30/2012 Sell To Open ONTY Feb12 5 Put $0.50
01/22/2012 Buy To Close EXPIRED ONTY JAN12 $5 PUT
01/09/2012 Sell To Open ONTY Jan12 5 Put $0.30

Oncothyreon Inc.(ONTY), a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its primary product candidate, Stimuvax is in Phase III clinical trials for the treatment of non-small cell lung cancer. The company also develops PX-866, a small molecule that is in Phase II trials. In addition, it engages in the preclinical development of ONT-10, a cancer vaccine. The company operates in Canada, the United States, Barbados, and Europe. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.

Oncothyreon Inc

2601 Fourth Avenue Suite 500

Seattle, WA 98121 Phone: 206-801-2100 Fax: 206-801-2101

Website: http://www.oncothyreon.com

News:

PAAS @ $12.40

Hold

there are no good options at this time.

History:

Cost basis $36.00 per share.

Premiums collected: $3.50 per share

Dividends : .35c

Total: $3.73

10.69% Return in 26 months

$10,000 would have generated $1069.00

actual trades:

05/19/2013 PAAS – PAAS QUALIFIED DIVIDEND .125 03/19/2013 PAAS – PAAS QUALIFIED DIVIDEND .125 12/04/2012 PAAS – PAAS QUALIFIED DIVIDEND .125

09/24/2012 Sell To Open PAAS Jan13 40 Call $0.05
01/30/2012Sell To Open PAAS Jul12 36 Call $0.20
12/06/2011 PAAS – PAAS QUALIFIED DIVIDEND $.025
10/24/2011 Sell To Open PAAS Jan12 36 Call $0.40
10/22/2011 Buy To Close EXPIRED PAAS Oct11 36 Call
09/08/2011 PAAS – PAAS QUALIFIED DIVIDEND $.025
06/20/2011 Sell To Open PAAS Oct11 36 Call $0.80
06/19/2011 Buy To Close EXPIRED PAAS JUN11 36 CALL
06/16/2011 PAAS QUALIFIED DIVIDEND $.025
05/23/2011 Sell To Open PAAS Jun11 36 Call $0.50
05/20/2011 Buy PAAS – Option Assignment $36.00
05/20/2011 Buy To Close PAAS May11 36 Put $0.00
04/18/2011 Sell To Open PAAS May11 36 Put $1.55

Pan American Silver Corp. engages in the exploration, development, extraction, processing, production, refining, reclamation, and operation of silver properties. The company also produces and sells gold, zinc, lead, and copper. As of April 27, 2011, it had seven silver mining operations in Mexico, Peru, Argentina, and Bolivia. The company was founded in 1979 and is headquartered in Vancouver, Canada.

Pan American Silver Corp.

625 Howe Street Suite 1500

Vancouver, BC V6C 2T6 Phone: 604-684-1175 Fax: 604-684-0147

Website: http://www.panamericansilver.com

News:http://www.fool.com/investing/general/2013/05/14/pan-american-silver-to-pay-its-second-dividend.aspx

PAY @ $18.13

Hold: no good options at this time.

History:

Cost basis $43.00 per share. Premiums collected: $3.36 per share 7.63% Return in 24 months

$10,000 would have generated $758.00

actual trades:

10/22/2012 Sell To Open PAY Jan13 44 Call $0.10

06/18/2012 Sell To Open PAY Oct12 $44 Call $0.35

05/21/2012 Sell To Open PAY Jun12 50 Call $1.00

04/16/2012 Sell To Open PAY May12 57.5 Call $1.02

04/16/2012 Buy To Close PAY Apr12 49 Call -$5.36

01/23/2012 Sell To Open PAY Apr12 49 Call $0.40

01/22/2012 Buy To Close EXPIRED PAY JAN12 49 CALL

10/31/2011 Sell To Open PAY Jan12 49 Call $0.90

10/31/2011 Buy To Close PAY Jan12 46 Call -$1.90

10/24/2011 Sell To Open PAY Jan12 46 Call $1.10

10/22/2011 Buy To Close EXPIRED PAY Oct11 42 Call

08/23/2011 Sell To Open PAY Oct11 42 Call $0.60

08/21/2011 Buy To Close EXPIRED PAY AUG11 46 Call

07/19/2011 Sell To Open PAY Aug11 46 Call $1.05

07/17/2011 Buy To Close EXPIRED PAY JUL11 44 Call

06/20/2011 Sell To Open PAY Jul11 44 Call $0.75

06/17/2011 Buy To Close PAY Jun11 43 Put $0.00

06/17/2011 Buy PAY – Option Assignment $43.00

05/23/2011 Sell To Open PAY Jun11 43 Put $1.70

VeriFone Systems, Inc. designs, markets, and services electronic payment solutions that enable secure electronic payments among consumers, merchants, and financial institutions worldwide. The company provides countertop electronic payment systems that accept magnetic, smart card, and contactless/radio frequency identification cards; and support credit, debit, check, electronic benefits transfer, and various pre-paid products, as well as offers wireless system solutions. The company also provides products for the point of sale applications, which include displays, user-friendly interfaces, electronic cash registers (ECR) interfaces, durable key pads, and signature capture functionality; and contactless/near field communication (NFC) payment solutions for consumer-activated transactions using contactless cards, tokens, or NFC enabled mobile phones. In addition, it offers various products for petroleum companies, such as integrated electronic payment systems that combine card processing, fuel dispensing, and ECR functions, as well as secure payment systems for integration with petroleum pump controllers and systems. Further, the company provides server-based transaction products; secure payment hardware and software integration modules; and VeriShield Protect, a solution that encrypts and protects consumer card data. Additionally, it offers client services, including payment system consulting, deployment, on-site and telephone-based installation and training, help desk support, repairs, replacement of impaired system solutions, asset tracking, and reporting; and project management services. The company serves financial institutions, payment processors, petroleum companies, retailers, government organizations, and healthcare companies, as well as independent sales organizations. The company was formerly known as VeriFone Holdings, Inc. and changed its name to VeriFone Systems, Inc. in May 2010. The company is headquartered in San Jose, California.

VeriFone Systems, Inc

2099 Gateway Place Suite 600

San Jose, CA 95110

Phone: 408-232-7800 Fax: 408-232-7811

Website: http://www.verifone.com

News:

TRGT @ $5.18

Hold

Take no action

There is no good option interest at this time.

History:

Cost basis $12.50 per share.

Premiums collected: $2.25 per share 18% Return in 21 months

$10,000 would have generated $1800.00

actual trades:

02/21/2012 Sell To Open TRGT May12 15 Call $0.25

11/28/2011 Sell To Open TRGT Feb12 15 Call $0.40

11/18/2011 Buy To Close TRGT Nov11 12.5 Put

11/18/2011 Buy TRGT – Option Assignment $12.50 10/23/2011 Sell to Open TRGT Nov 11 $12.50 PUT $1.60

Targacept, Inc., a biopharmaceutical company, engages in the design, discovery, and development of novel Neuronal Nicotinic Receptors (NNR) Therapeutics for the treatment of diseases and disorders of the nervous system. Its lead program, TC-5214, a nicotinic channel modulator, is in Phase 3 clinical trials as an adjunct treatment for major depressive disorder (MDD) and in Phase 2b clinical trial for switch monotherapy in patients with MDD.


The company s novel small molecule product candidates under Phase 2 clinical development include TC-5619 for treating negative symptoms and cognitive dysfunction in schizophrenia, attention deficit/hyperactivity disorder, and Alzheimer s disease; AZD3480 as a treatment for mild to moderate Alzheimer s disease; AZD1446 as a treatment for Alzheimer s disease; and TC-6987 for the treatment of inflammatory disorders, including asthma and Type 2 diabetes. It has a collaborative research and license agreement with AstraZeneca AB for the development and commercialization of AZD3480, TC-5214, and TC-5619; and a product development and commercialization agreement with SmithKline Beecham Corporation to discover, develop, and market product candidates that selectively target specified NNR subtypes in specified therapeutic focus areas. The company was founded in 1997 and is based in Winston-Salem, North Carolina.

Targacept, Inc.

200 East First Street Suite 300

Winston-Salem, NC 27101-4165 Phone: 336-480-2100

Fax: 336-480-2107

Website: http://www.targacept.com

News:

ZIOP @ $2.79

ZIOPHARM Oncology, Inc.

Hold: January 2014 $5 Call still cooking

History:

Cost basis $3.00 per share. Premiums collected: $.25 per share 8.33% Return in 4 months

$10,000 would have generated $666.00

actual trades:

04/22/2013 Sell To Open ZIOP Jan14 $5 Call $0.05 04/19/2013 Buy ZIOP – Stock Assignment $ 3.00 03/18/2013 Sell To Open ZIOP Apr13 3 Put $0.20

ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of new cancer therapies. Its lead candidate, Palifosfamide (ZIO-201), a potent bi-functional DNA

alkylating agent, is under Phase III trial for the treatment of first -line metastatic soft tissue sarcoma, as well as in a pivotal Phase III trial for first-line metastatic small cell lung cancer. The company s portfolio of clinical-stage product candidates also include IL-12 DNA, which is being tested in a Phase 2 study using synthetic biology to enable controlled, local delivery of therapeutic interleukin-12; Indibulin (ZIO-301), a novel, tubulin binding agent under Phase I/II trial in metastatic breast cancer; and Darinaparsin (ZIO- 101), a novel mitochondrial- and hedgehog-targeted agent. In addition, its portfolio comprises various research-stage candidates. The company s DNA therapeutics are being developed in partnership with Intrexon Corporation through a synthetic biology platform that allows for targeted, controlled production of therapies in humans with a biologic on/off switch. ZIOPHARM Oncology, Inc. was founded in 2003 and is headquartered in New York, New York with operations center located in Boston, Massachusetts.

ZIOPHARM Oncology, Inc.

1180 Avenue of the Americas 20th Floor

New York, NY 10036

Phone: 646-214-0700 Fax: 646-214-0711

Website: http://www.ziopharm.com

News:

ZNGA @ $3.36

Hold

Take no action

There is no good option interest at this time.

History:

Cost basis $14.00 per share. Premiums collected: $2.05 per share 14.64% Return in 17 months

$10,000 would have generated $1464.00

actual trades:

03/19/2012 Sell To Open ZNGA Apr12 16 Call $0.20

03/18/2012 Buy To Close EXPIRED ZNGA MAR12 15 CALL

02/21/2012 Sell To Open ZNGA Mar12 15 Call $0.40

02/17/2012 Buy ZNGA – Option Assignment $14.00

02/17/2012 Buy To Close ZNGA Feb12 14 Put
02/06/2012 Sell To Open ZNGA Feb12 14 Put$1.55

Zynga Inc. develops, markets, and operates online social games as live services on the Internet, social networking sites, and mobile platforms. The company offers its online social games under the CityVille, Zynga Poker, FarmVille, CastleVille, FrontierVille, Mafia Wars, Word with Friends, Hidden Chronicles, Zynga Bingo, Scramble With Friends, Slingo, and Dream Heights names. Its games are available on various platforms, including Facebook and other social networks, as well as mobile platforms, such as Apple iOS and Google Android worldwide. The company was formerly known as Zynga Game Network Inc. and changed its name to Zynga Inc. in November 2010. Zynga Inc. was founded in 2007 and is headquartered in San Francisco, California.

Zynga, Inc.

699 Eighth Street

San Francisco, CA 94103 Phone: 855-449-9642 Fax: 302-636-5454

Website: http://www.zynga.com

News:

Quote of the Month:

“Only those who will be sellers of equities in the near future should be happy at seeing stocks rise. Prospective purchasers should much prefer sinking prices.” * ( this is important)

~ Warren Buffet

Until Next Time

Brad Lee

The Options Oracle

https://theoptionsoracle.com/

The place for safer Investments

Ask The Oracle
Webinar Sunday 8 pmESTto
explain this newsletter, or other questions
you might have.
Here is the link
http://www.anymeeting.com/MoneyMedic1
There is no preregistration.
Please use the phone option for audio
Summary of Trades:
Cash Covered Puts
Sell To Open GTXI Aug 2013 $2
Put @ Market
Sell To Open HLF Aug 2013 $50
Put @ Market
Stock Covered Calls
no covered calls
Called away:
07/19/2013 SCTY – Stock
Assignment $40.00
20% Return in 2 months
07/19/2013 ELN – Option
Assignment $13.00
23.33% Return in 10 months
Past performance click here
https://theoptionsoracle.com/past-performances/

Company News

Feel free to contact me personally!

After dozens of suggestions we decided to add this service.

Got a question or concern? Want to learn my philosophy and why it pays so well and consistently? Go to “contact us” https://theoptionsoracle.com/contacting-us/

and schedule a consultation. It is free and now included as part of our service.

Military discounts are here!

Thank you for your service!

Refer a Friend

The greatest compliment you can give me is to share me with your friends.

Disclosure: These are my actual trades.

I am not telling you what to do, I am showing you what I am doing.

Your subscription fee may be 100% TAX DEDUCTIBLE if used for educational business/investment purposes. Check with your Licensed Professional adviser

Company News
Auto Trading is now active!
Don’t want to be bothered doing the
trades?
Auto-trading is for you. Your account will
automatically do whatever I do.
You are still in control, you set the limits
either a dollar amount or a percentage.
Go to the main site, the Auto-trade link is
on the site
https://theoptionsoracle.com/auto-trading/

We will be doing a webinar Sunday
8 pm est to explain this newsletter.
Here is the link
http://www.anymeeting.com/MoneyMedic
Disclosure: These are my actual trades.
Your subscription fee may be 100% TAX

DEDUCTIBLE if used for educational

business/investment purposes. Check

with your Licensed Professional adviser
Options involve risk and are not suitable for all
investors. Prior to trading options, you must be
approved for options trading and read the
Characteristics and Risks of Standardized
Options.
Copies of this document may also be obtained
from your broker, from any exchange on which
options are traded, by placing an order online,
or by contacting the Options Clearing
Corporation directly at 1 N. Wacker Dr., Suite
500, Chicago, IL 60606. (1-888-678-4667).
Brad Lee AKA “The Options Oracle” and
“The Money Medic” is an individual
investor who does not manage money for

any financial institution. You are
purchasing the list of stocks that he uses to
select options contracts he feels will return
him the highest, safest profits. Brad is not
a broker, or financial adviser. He is a
remarkable investor who has developed a
successful strategy for himself, and is
willing to share some of his magic with you. We urge you to paper trade these picks and learn how to develop a strategy that is appropriate for you. Thank You. We make no recommendations on investment and we do not provide financial, tax or legal advice. Content and tools are provided for educational and informational purposes only.

Disclaimer

Trading or investment in stocks, futures & options, and commodity are subject to potential market risks. You can use our materials or recommendations for educational purposes, this is not intended as Trading or Investment advice. We are not financial advisers. We cannot provide any advice as to whether or not options or our trading ideas are suitable investments for your particular financial situation. We are in the business of publishing our trade ideas for market analysis only. We highly recommend that our subscribers review their trading allocation with a qualified registered financial adviser/planner.

Legal Disclaimer: we do not exist to render and do not give legal, tax, economic or investment advice and disclaims all liability for the actions or inaction taken or not as a result of communications from or to its members, officers, directors, employees and contractors. Each individual should consult his/her own counsel, accountant and other advisors as to legal, tax, economic, investment and related matters concerning any type of investments.

This email and any files transmitted with it are solely intended for the use of the addressee(s) and may contain information that is confidential and privileged. If you receive this email in error, please advise us by return email immediately. Please also disregard the contents of the email, delete it and destroy any copies immediately.